PREVALENCE OF SENSITISATION TO SOYA FLOUR IN THE BAKING INDUSTRY WITHIN THE UK

1J Szram, 2SJ Schofield, 3IA Mollan, 3GD a v i e s , 3D Bruce, 2P Cullinan.
1Royal Brompton Hospital, London, UK; 2Imperial College, London, UK
3The Royal Air Force Medical Branch, UK

Introduction Soya flour is routinely used as a baking additive to increase shelf life, improve colour and introduce a nutty flavour to bread. Although a large number of bakers are exposed to soya flour, there is little information as to the prevalence of sensitisation to soya flour in the baking industry. One study reports sensitisation to soya flour in four bakers who were sensitised to flour and alpha amylase and a bronchial challenge to soya flour elicited an immediate or dual asthmatic response. Studies in soy processing plant (slightly different to bakeries) report soy-specific IgE in 21% of soy processing workers compared with only 4% in health care workers, suggesting soya is an important occupational allergen in the soy processing industry.

Methods To determine prevalence of sensitisation to soya flour in bakery workers, we carried out skin prick testing to soya flour (Allergopharma 598) in bakery workers exposed to soya flour (n = 196) and in non-bakery controls (n = 50), who attended an occupational lung disease clinic. Skin tests were categorised as positive if they induced a wheal with a mean diameter of ≥2 mm greater than the response to a negative (saline) control and histamine was used as a positive control.

Results In a total of one hundred and ninety five bakery workers exposed to soya, forty two bakers were sensitised to soya flour (21%), and forty of those bakers were also sensitised to either flour and or alpha amylase (95%). In comparison, none of the control group (n = 50) were sensitised to soya flour.

Conclusion In our preliminary study of bakery workers exposed to soya flour, we found that around a fifth of the population were sensitised to soya flour. The clinical significance of soya flour need further investigation, although it seems prudent to include soya flour in the diagnostic tests for bakers asthma.

P149 CHARACTERISTIC AND PROGNOSIS OF PATIENTS WITH COPD AND TYPE 2 RESPIRATORY FAILURE

T Spruell, C Dave, R Mukherjee, AM Turner. Birmingham Heartlands Hospital, Birmingham, UK

Introduction Factors associated with type 2 respiratory failure (T2RF) in COPD have been poorly described. Co-existent obstructive sleep apnoea is thought to play a part, and episodes of worsening hypercapnia, associated with acidosis (AHRF), at the time of exacerbations is a well recognised feature. We hypothesised that the development of hypercapnia or type 2 respiratory failure would associate with a higher risk of subsequent AHRF and higher mortality.

Methods 292 patients who had been prescribed oxygen for their COPD during 2006–2010 were studied. Medical records were
HOSPITAL RE-ADMISSIONS WITH EXACERBATION OF OBSTRUCTIVE PULMONARY DISEASE IN ILlicit DRUG SMOKERS

R Yadavilli, R Huang, AM Collins, W Yew Ding, N Gamer, J Williams, H Burhan. Royal Respiratory Research (RRR). The Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK

10.1136/thoraxjnl-2014-206260.279

Introduction Patients with obstructive pulmonary disease (asthma or chronic obstructive pulmonary disease – COPD) who smoke illicit drugs are at an increased risk of hospital admissions.

We compared hospital re-admission rates due to exacerbations of obstructive pulmonary disease amongst current/ex- illicit drug smokers versus current/ex-tobacco smokers.

Hypothesis ‘Are those who smoke illicit drugs admitted to hospital with a clinical diagnosis of exacerbation of COPD more likely to be re-admitted with a further exacerbation than current/ex-tobacco smokers?’

Methods Re-admission was defined as any admission, after the first, with an exacerbation of obstructive pulmonary disease during the study period. All admissions with a presumptive diagnosis of ‘exacerbation of COPD’ between January 2009 and September 2011 were reviewed. This was performed retrospectively using our COPD admission database.

Results There were 950 sequential hospital admissions in 709 patients over a 33 month period. We found 230 ex-tobacco smokers, 370 current tobacco smokers and 89 current or ex-illicit drug smokers. Re-admission rates with exacerbation of obstructive pulmonary disease were higher in illicit drug smokers compared to current/ex-tobacco smokers (1.00 v. 0.22/0.26, p < 0.001). Illicit drug smokers were younger (50 v. 72.9/69.9 [mean 71.2] years, p < 0.001) and had shorter length of hospital stay (7.44 v. 9.28/10.69 [mean 9.87] days, p = 0.038). Illicit drug smokers with FEV1 < 1 litre (L) had higher readmissions (2.56) than ex/current tobacco smokers (0.6) with FEV1 < 1L (p < 0.001) [Table 1]. Illicit drug smokers with FEV1 > 1L did not show this trend (p = 0.236). Tobacco pack years were higher in tobacco smokers (40.22) compared to illicit drug smokers (22.47), p. Admissions requiring non-invasive ventilation (NIV) for type 2 respiratory failure were more common in illicit drug smokers (8.4 v. 3%, p < 0.002).

Conclusion We have shown that readmission rates in illicit drug smokers are higher than in tobacco smokers. These patients tend to be younger, have a male predominance, have shorter length of hospital stay and are more likely to require NIV; readmissions were more predominant in illicit drug smokers with an FEV1<1.

Can the Decaf Score Be Used to Guide Prognosis After an Acute Admission for COPD Exacerbation?

B Rabbani, P Brammer. The Dudley Group NHS Foundation Trust, West Midlands, UK

10.1136/thoraxjnl-2014-206260.280

Introduction Each year chronic obstructive pulmonary disease (COPD) causes approximately 23,000 deaths in England. Patients are admitted daily with exacerbation of COPD which can often be life-threatening. Steer et al have shown the use of DECAF score to predict inpatient mortality in COPD exacerbation. The DECAF score stratifies patients into low, intermediate and high risk dependent on their admission score.